Joshua Lin and Team: New Evidence on Long-Term Anticoagulation for Unprovoked VTE
Joshua Lin, Executive Director of Mass General Brigham Center for Integrated Healthcare Data Research, posted on LinkedIn:
”New Evidence on Long-Term Anticoagulation for Unprovoked VTE
We are pleased to share our recent BMJ publication demonstrating that continuation of oral anticoagulant therapy beyond the initial 90-day treatment period after a first unprovoked venous thromboembolism (VTE) is associated with a significantly lower risk of recurrent thrombosis and all-cause mortality, compared with early discontinuation. Extended therapy, however, is also associated with a higher risk of major bleeding – underscoring the importance of individualized clinical decision-making.
Full study here.
Press Release here.”
Title: Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation
Authors: Kueiyu Joshua Lin, Dae Hyun Kim, Daniel E Singer, Yichi Zhang, Alexander Cervone, Anna R Kehoe, Katsiaryna Bykov
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch